News|Articles|November 20, 2026

Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada

Yuvezzi Health Canada submission builds on BRIO-I and BRIO-II phase 3 data.

Tenpoint Therapeutics has filed a New Drug Submission (NDS) with Health Canada for carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi'; Tenpoint Therapeutics) to treat presbyopia in adults, according to a news release. The FDA approved the once-daily, dual-agent drop in January 2026. It was the first combination eye drop approved for presbyopia in the US.1,2

The NDS is supported by 2 phase 3, randomized, double-masked, controlled studies, BRIO-I and BRIO-II.1 BRIO-I was designed to meet FDA requirements for fixed-dose combinations by showing the combination is superior to each of its components. According to the sponsor, Yuvezzi provided greater near-vision benefit than either carbachol or brimonidine alone.2

Yuvezzi had joined a growing set of pharmacologic presbyopia options available to US optometrists, including pilocarpine 0.4% (Qlosi; Orasis Pharmaceuticals) and aceclidine 1.44% (Vizz; Lenz Therapeutics).3 Its fixed-dose formulation pairs carbachol, a miotic, with brimonidine, which limits pupil dilation, giving ODs a combination approach different from single-agent drops.1

BRIO-II was a vehicle-controlled trial evaluating binocular uncorrected near visual acuity (BUNVA) over eight hours after once-daily dosing. Its primary endpoints were a 3-line or greater gain in BUNVA without a loss of 1 line or more in binocular uncorrected distance visual acuity (BUDVA).2 Yuvezzi met these endpoints, with statistically significant near-vision improvements vs vehicle at all time points out to eight hours (P < .008).4

The trial’s primary end points were agreed upon with the FDA, the European Medicines Agency, and the UK Medicines and Healthcare products Regulatory Agency.4 Numerical responder rates and full statistical methods have not been publicly reported.2

Miosis duration, tolerability, and long-term safety

Yuvezzi produced miosis from 30 minutes up to 10 hours after a single daily drop.1 The company reported clinically and statistically significant reductions in pupil size at all time points, with miosis gradually resolving over 10 hours. According to Tenpoint, less miosis later in the day may reduce difficulty with night vision.4

Tenpoint also reported improved distance vision alongside the near-vision gains. No tachyphylaxis in vision or pupil effects was observed during the 12-month at-home dosing phase of BRIO-II.4 The sponsor describes this 12-month safety cohort as the longest safety follow-up reported for a presbyopia eye drop.2

Yuvezzi was well tolerated, with no treatment-related serious adverse events across more than 72,000 dosing days monitored in BRIO-II.1 According to the company, adding brimonidine reduced the incidence of hyperemia compared with carbachol alone.4 Ocular redness is a common patient-reported concern with miotic therapy, so this finding is relevant to anterior segment tolerability.

“Our submission of YUVEZZI to Health Canada demonstrates our continued ambition to bring this treatment to patients around the world,” Henric Bjarke, chief executive officer of Tenpoint, said in the announcement.

Health Canada has not yet ruled on the submission, and Tenpoint did not give a review timeline.1 Canadian optometrists will need to wait for a decision before prescribing Yuvezzi. In the US, ODs can prescribe the FDA-approved drop within their state scope of practice.

For presbyopic patients interested in drop-based near-vision correction, chair-side counseling should cover onset of about 30 minutes, effect duration of up to 10 hours, and expectations for dim-light vision.1,4 The combination’s distance-vision profile and its once-daily dosing may help ODs choose among the miotic options now on the market.

References
  1. Tenpoint Therapeutics announces New Drug Submission to Health Canada for Yuvezzi for the treatment of presbyopia in adults. News release. Tenpoint Therapeutics. November 20, 2026. Accessed November 20, 2026. https://www.businesswire.com/news/home/20261120088446/en/Tenpoint-Therapeutics-Announces-New-Drug-Submission-to-Health-Canada-for-the-Treatment-of-Blurry-Close-Up-Vision-Presbyopia-in-Adults
  2. Stevenson S. FDA decision: carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results. Ophthalmology Times. January 29, 2026. Accessed November 20, 2026. https://www.ophthalmologytimes.com/view/fda-decision-carbachol-brimonidine-ophthalmic-solution-approved-for-presbyopia-following-brio-phase-3-results
  3. Joy J. FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia. Optometry Times. January 29, 2026. Accessed November 20, 2026. https://www.optometrytimes.com/view/fda-approves-yuvezzi-carbachol-and-brimonidine-tartrate-ophthalmic-solution-2-75-0-1-for-presbyopia
  4. Tenpoint Therapeutics announces positive topline data from phase 3 pivotal study, BRIO-II, of BRIMOCHOL PF for the treatment of presbyopia. News release. Tenpoint Therapeutics. January 9, 2025. Accessed November 20, 2026. https://businesswire.com/news/home/20250109824922/en

Related to this article